Chemokine production by adenovirus-infected or LPS-treated human monocytes
Treatment . | MIP-1α . | MIP-1β . | RANTES . |
---|---|---|---|
Donor 1 | |||
SFM/G | < .062 | < .062 | < .016 |
Plus adenovirus-GFP | 40 | 79 | 14 |
Plus LPS | 74 | 181 | 61 |
Donor 2 | |||
SFM/G | < .062 | < .062 | < .016 |
Plus adenovirus-GFP | 15 | 46 | 12 |
Plus LPS | 30 | 163 | 16 |
Treatment . | MIP-1α . | MIP-1β . | RANTES . |
---|---|---|---|
Donor 1 | |||
SFM/G | < .062 | < .062 | < .016 |
Plus adenovirus-GFP | 40 | 79 | 14 |
Plus LPS | 74 | 181 | 61 |
Donor 2 | |||
SFM/G | < .062 | < .062 | < .016 |
Plus adenovirus-GFP | 15 | 46 | 12 |
Plus LPS | 30 | 163 | 16 |
Human CD14+ monocytes were cultured for 36 hours in macrophage serum-free medium and granulocyte-macrophage colony-stimulating factor and then were infected with adenovirus-GFP (200 plaque-forming units per cell) or treated with lipopolysaccharide (50 ng/mL). At 48 hours later, supernatants were assayed for the indicated chemokines. Results are expressed in nanograms per milliliter.
MIP indicates macrophage inflammatory protein; SFM/G, macrophage serum-free medium and granulocyte-macrophage colony-stimulating factor; GFP, green fluorescent protein; and LPS, lipopolysaccharide.